Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes Care securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Insights - The smart pill market is projected to grow from USD 8.5 billion in 2024 at a CAGR of 15.7% from 2025 to 2035, driven by increasing health consciousness and rising colon cancer cases globally [1][3]. Growth Drivers - The aging global population and the rising incidence of chronic illnesses, including colon cancer, diabetes, and cardiovascular problems, are significant factors driving market expansion [3][4]. - Technological advancements in capsule endoscopy and the demand for rapid medication development are contributing to market growth [2][4]. - Increased healthcare costs and a growing preference for non-invasive procedures are also fueling the market [1]. Market Segmentation - Applications include capsule endoscopy, targeted drug delivery, and vital sign monitoring [8]. - Target areas encompass the esophagus, small intestine, large intestine, and stomach [8]. - End users consist of hospitals, diagnostic centers, and others [8]. Regional Outlook - The market is segmented into various regions, including Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa [8]. Key Players - Major companies in the smart pill market include Chongqing Jinshan Science Technology, Check-Cap Ltd, Shenzhen Jifu Medical Technology Limited, Olympus Corporation, Otsuka America Pharmaceutical Co., Capsovision Inc, and Medtronic Plc [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of federal securities law violations related to the Novum LVP device, which reportedly suffered systemic defects leading to serious patient risks [3][4]. Group 1: Allegations Against Baxter - The complaint alleges that Baxter and its executives made false or misleading statements regarding the Novum LVP, failing to disclose systemic defects that caused malfunctions, including underinfusion and overinfusion, which posed risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to continued harm to patients [3]. - As a result of these issues, there was a heightened risk that existing Novum LVPs would be taken out of service, and Baxter would halt all new sales of these pumps [3]. Group 2: Impact on Stock and Legal Proceedings - The true extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [4]. - Investors who purchased Baxter securities between February 23, 2022, and July 30, 2025, are encouraged to discuss their legal rights and options, with a deadline of December 15, 2025, to seek the role of lead plaintiff in the class action [1][5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to allegations of misleading statements regarding the launch of its Inspire V device, which has faced significant setbacks and weak demand, leading to a substantial drop in stock price and market capitalization [2][4][6]. Group 1: Legal Investigation - Faruqi & Faruqi is encouraging investors who suffered losses in Inspire Medical to contact them for discussing legal options [1]. - A federal securities class action has been filed against Inspire Medical, with a deadline of January 5, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Company Performance and Issues - Inspire Medical announced significant setbacks in the launch of its Inspire V device on August 4, 2025, citing delays in training and onboarding at treatment centers [5]. - The company faced billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, 2025, affecting the ability to bill for procedures [5]. - Inspire Medical reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [6]. Group 3: Market Impact - Following the announcement of setbacks, Inspire Medical's stock price plummeted over 32% in one day, from $129.95 to $87.91, resulting in a loss of approximately $1.2 billion in market capitalization [6].

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 15, 2025, to represent other class members [4][6]. Group 2: Allegations Against Baxter - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which caused malfunctions that posed serious risks to patients [6]. - Specific issues included underinfusion, overinfusion, and complete non-delivery of fluids, along with inadequate responses to reported malfunctions and injuries [6]. - The lawsuit claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, leading to investor damages when the truth was revealed [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [5].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a proposed class-action lawsuit for allegedly misleading investors regarding the commercial readiness and demand for its Inspire V sleep apnea device, leading to a significant stock decline [1][6]. Company Overview - Inspire Medical Systems, Inc. is under investigation by prominent investor rights law firm Hagens Berman for claims related to investor losses during the class period from August 6, 2024, to August 4, 2025 [2][3]. Allegations of Misleading Information - The lawsuit claims that Inspire provided repeated assurances about meeting all regulatory and commercial prerequisites for the Inspire V launch while promoting high demand, which was later revealed to be untrue [3][4]. - The complaint highlights that the actual launch of Inspire V was disastrous, with minimal initial demand attributed to customers being overstocked with the older Inspire IV devices [4][5]. Impact of the Launch - On August 4, 2025, Inspire disclosed that the launch faced an "elongated timeframe" due to undisclosed challenges, including incomplete training and onboarding at implanting centers [5][6]. - The company noted that although the CPT code for Medicare patients was approved, software updates for claims processing did not take effect until July 1, delaying billing for procedures and leading centers to continue using the older Inspire IV [5][6]. Financial Consequences - As a result of the poor launch performance, Inspire slashed its 2025 earnings guidance by 80%, projecting earnings of only $0.40 to $0.50 per share [6]. - Following this announcement, Inspire's stock price plummeted by approximately 32%, dropping $42.04 the next day [6].

Core Insights - SG Capital Management LLC reduced its holding in Haemonetics Corporation by 731,892 shares, resulting in a position value decline of approximately $59.1 million as of November 7, 2025 [1][2]. Company Overview - Haemonetics Corporation is a leading provider of medical devices and software for blood and plasma management, addressing critical needs in transfusion medicine and plasma collection through a diversified product portfolio and integrated technology platforms [5][6]. - The company generates revenue primarily from the sale of medical devices, disposables, and integrated software solutions to healthcare providers and plasma collection centers globally [6]. Financial Performance - For the trailing twelve months (TTM), Haemonetics reported revenue of $1.33 billion and net income of $168.19 million [4]. - The company's share price as of November 6, 2025, was $67.11, reflecting a 14.14% decline over the past year, underperforming the S&P 500 by 27.5 percentage points [4][10]. Recent Developments - Haemonetics reported a 5% decline in revenue for the fiscal second quarter, totaling $327 million, with a 1.8% drop when excluding foreign-currency exchange impacts and divestitures [8]. - Management's guidance for the full year's adjusted revenue indicates a potential decline of 1% to an increase of 2%, which is an improvement from previous guidance [9]. Investment Activity - Following the reduction in its stake, Haemonetics now accounts for only 0.8% of SG Capital's total 13F assets under management (AUM), down from 4.7% in the prior quarter [10]. - The market reacted positively to Haemonetics' results and guidance, with the share price increasing by 35% in the two days following the earnings release [11].

Core Viewpoint - Grabar Law Office is investigating claims on behalf of Inspire Medical Systems, Inc. shareholders regarding potential breaches of fiduciary duties by certain officers of the company [1] Investigation Basis - A securities fraud class action complaint alleges that Inspire Medical misled investors about the launch of its key product, the Inspire V sleep apnea device, claiming it met all necessary conditions for a successful launch, while in reality, the launch faced significant issues [3] - The complaint states that demand for Inspire V was low due to customers having excess inventory of older devices, and that the company failed to ensure proper uptake by clinicians and payors, leading to delays in adoption [3] - Following the revelation of these issues on August 4, 2025, Inspire Medical's stock price dropped by 32%, resulting in a loss of over $1.5 billion in shareholder value [3] Actions for Shareholders - Current shareholders who have held Inspire Medical shares since before August 6, 2024, can pursue corporate reforms, seek the return of funds to the company, and obtain a court-approved incentive award at no cost [2][4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The deadline to move the Court to serve as lead plaintiff is December 15, 2025, with the lead plaintiff acting on behalf of other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific claims include that Baxter was aware of multiple device malfunctions and that its remedial measures were inadequate, resulting in a heightened risk of product recalls and sales pauses [5] - The lawsuit asserts that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, causing investor damages when the truth was revealed [5]

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for securities fraud due to significant stock drops linked to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until December 26, 2025, to request to lead the case in the U.S. District Court for the Southern District of New York [3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Product Issues - DexCom manufactures continuous glucose monitoring systems, including the G6 and G7, which were marketed as highly accurate [4]. - Allegations state that unauthorized design changes were made to the G6 and G7, compromising their accuracy and posing health risks to customers [5]. Group 3: Stock Performance - DexCom's stock experienced significant declines due to revelations about product quality issues, including a drop of $7.12 per share (over 9%) following an FDA warning letter on March 7, 2025 [6]. - After the FDA published details of unauthorized modifications on March 25, 2025, the stock fell another $3.19 per share (over 4%) [7]. - A report by Hunterbrook on September 18 revealed severe issues, leading to a nearly 12% drop of $8.99 per share over two trading days [8].